Xenetic Biosciences Q2 2025 Earnings Narrowed Loss Exceeds Expectations Amid Oncology Pipeline Progress CDE Q1 2026 Earnings EPS Misses Estimates but Stock Rises 23 Armata Pharmaceuticals ARMP Q1 2026 Earnings Steep EPS Miss as ClinicalStage Biotech Continues Heavy RD Spending Flexible Solutions International FSI Q1 2026 Earnings EPS Misses Estimates Significantly Stock Rises Unexpectedly StoneX Group Q1 2026 Earnings EPS Surges Past Estimates with 365 Surprise NVCT Q1 2026 Earnings Narrower Loss Beats Estimates as Clinical Pipeline Advances